title: A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women.
abstract: BACKGROUND
  The relationship between CETP and postprandial hyperlipemia is still unclear. We verified the effects of varying activities of plasma CETP on postprandial lipemia and precocious atherosclerosis in asymptomatic adult women.
  
  
  METHODS
  Twenty-eight women, selected from a healthy population sample (n = 148) were classified according to three CETP levels, all statistically different: CETP deficiency (CETPd ≤ 4.5%, n = 8), high activity (CETPi ≥ 23.8, n = 6) and controls (CTL, CETP ≥ 4.6% and ≤ 23.7%, n = 14). After a 12 h fast they underwent an oral fat tolerance test (40 g of fat/m² of body surface area) for 8 hours. TG, TG-rich-lipoproteins (TRL), cholesterol and TRL-TG measurements (AUC, AUIC, AR, RR and late peaks) and comparisons were performed on all time points. Lipases and phospholipids transfer protein (PLTP) were determined. Correlation between carotid atherosclerosis (c-IMT) and postprandial parameters was determined. CETP TaqIB and I405V and ApoE-ε3/ε2/ε4 polymorphisms were examined. To elucidate the regulation of increased lipemia in CETPd a multiple linear regression analysis was performed.
  
  
  RESULTS
  In the CETPi and CTL groups, CETP activity was respectively 9 and 5.3 higher compared to the CETPd group. Concentrations of all HDL fractions and ApoA-I were higher in the CETPd group and clearance was delayed, as demonstrated by modified lipemia parameters (AUC, AUIC, RR, AR and late peaks and meal response patterns). LPL or HL deficiencies were not observed. No genetic determinants of CETP deficiency or of postprandial lipemia were found. Correlations with c-IMT in the CETPd group indicated postprandial pro-atherogenic associations. In CETPd the regression multivariate analysis (model A) showed that CETP was largely and negatively predicted by VLDL-C lipemia (R² = 92%) and much less by TG, LDL-C, ApoAI, phospholipids and non-HDL-C. CETP (model B) influenced mainly the increment in ApoB-100 containing lipoproteins (R² = 85% negatively) and phospholipids (R² = 13%), at the 6(th)h point.
  
  
  CONCLUSIONS
  The moderate CETP deficiency phenotype included a paradoxically high HDL-C and its sub fractions (as earlier described), positive associations with c-IMT, a postprandial VLDL-C increment predicting negatively CETP activity and CETP activity regulating inversely the increment in ApoB100-containing lipoproteins. We hypothesize that the enrichment of TG content in triglyceride-rich ApoB-containing lipoproteins and in TG rich remnants increases lipoproteins' competition to active lipolysis sites,reducing their catabolism and resulting on postprandial lipemia with atherogenic consequences.
authors: Department of Clinical Pathology, Lipid Laboratory and Center for Medicine and Experimental Surgery, Faculty of Medical Sciences, University of Campinas, Rua Tessália Vieira de Camargo, Campinas 13084-971, Brazil.
authors: Eliane S
authors: ES
authors: Parra
authors: Aline
authors: A
authors: Urban
authors: Natalia B
authors: NB
authors: Panzoldo
authors: Rui T
authors: RT
authors: Nakamura
authors: Rogério
authors: R
authors: Oliveira
authors: Eliana C
authors: EC
authors: de Faria
references: J Atheroscler Thromb. 2005;12(2):73-6
references: 15942116
references: Arterioscler Thromb. 1992 Nov;12(11):1336-45
references: 1420093
references: Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1622-9
references: 10845881
references: Open Cardiovasc Med J. 2009 Jun 11;3:48-50
references: 19557147
references: Eur J Clin Invest. 2007 Feb;37(2):90-8
references: 17217373
references: J Biol Chem. 1998 Oct 9;273(41):26388-93
references: 9756870
references: JAMA. 2001 May 16;285(19):2486-97
references: 11368702
references: J Lipid Res. 1999 Jul;40(7):1185-93
references: 10393203
references: Metabolism. 1975 Nov;24(11):1243-65
references: 171539
references: Eur J Clin Invest. 2011 Sep;41(9):921-8
references: 21299553
references: Circulation. 1977 May;55(5):767-72
references: 191215
references: Circulation. 1989 Jan;79(1):8-15
references: 2642759
references: Circulation. 2010 Jan 26;121(3):366-74
references: 20065167
references: J Atheroscler Thromb. 2004;11(3):110-21
references: 15256762
references: Ann Clin Biochem. 2009 Nov;46(Pt 6):457-63
references: 19641010
references: IUBMB Life. 2011 Apr;63(4):248-57
references: 21488146
references: J Clin Invest. 1994 Nov;94(5):1872-82
references: 7962532
references: Eur J Clin Invest. 1999 Feb;29(2):116-28
references: 10092998
references: J Clin Invest. 1999 Apr;103(8):1191-9
references: 10207171
references: Vasc Med. 2004 Feb;9(1):46-54
references: 15230488
references: Am J Physiol. 1999 Mar;276(3):E553-7
references: 10070023
references: J Lipid Res. 1998 Jan;39(1):59-65
references: 9469586
references: J Lipid Res. 1981 Feb;22(2):339-58
references: 6787159
references: Metabolism. 2010 Jun;59(6):854-60
references: 20005542
references: Biochem Biophys Res Commun. 1993 Jul 15;194(1):519-24
references: 8333866
references: Atherosclerosis. 2009 Aug;205(2):506-11
references: 19200546
references: Int J Cardiovasc Imaging. 2010 Jan;26(1):27-34
references: 19876761
references: Genomics. 1988 Nov;3(4):373-9
references: 3243553
references: Lipids Health Dis. 2009 Jun 26;8:24
references: 19558660
references: Hypertension. 1999 Aug;34(2):217-21
references: 10454444
references: Biochim Biophys Acta. 1982 Sep 14;712(3):444-52
references: 7126618
references: J Lipid Res. 1996 Oct;37(10):2145-54
references: 8906592
references: J Lipid Res. 2009 Jun;50(6):1109-19
references: 19237736
references: Nature. 1989 Nov 23;342(6248):448-51
references: 2586614
references: Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):148-54
references: 17951324
references: Am J Cardiol. 2003 Aug 18;92(4A):42J-49J
references: 12957326
references: J Lipid Res. 2003 Jan;44(1):33-40
references: 12518020
references: Stroke. 1993 Sep;24(9):1297-304
references: 8362421
references: Lancet. 1975 Jan 4;1(7897):16-9
references: 46338
references: Biochemistry. 2007 Aug 21;46(33):9645-53
references: 17655277
references: J Clin Invest. 1995 Sep;96(3):1664-71
references: 7657837
references: Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3433-41
references: 9437190
references: Biochem J. 2009 May 1;419(3):629-34
references: 19191759
references: Pharmacol Ther. 2004 Jan;101(1):17-38
references: 14729390
references: Mol Cell Biochem. 2011 Jun;352(1-2):189-96
references: 21380728
references: J Biol Chem. 1998 Jul 10;273(28):17483-90
references: 9651338
references: J Lipid Res. 2006 Jul;47(7):1526-34
references: 16603720
references: J Lipid Res. 2009 Nov;50(11):2222-34
references: 19282272
references: Methods Mol Biol. 1998;110:231-41
references: 9918050
references: J Lipid Res. 2010 Nov;51(11):3350-8
references: 20713650
references: Atheroscler Suppl. 2010 Jun;11(1):39-43
references: 20434407
references: Eur Heart J. 2010 Jan;31(2):149-64
references: 19825813
references: JAMA. 2008 Jun 18;299(23):2777-88
references: 18560005
references: J Clin Endocrinol Metab. 2006 Sep;91(9):3382-8
references: 16684835
references: Arch Gerontol Geriatr. 2006 Sep-Oct;43(2):213-21
references: 16384616
references: World J Gastroenterol. 2010 Dec 21;16(47):5908-15
references: 21157966
references: J Am Coll Cardiol. 2006 Feb 7;47(3):492-9
references: 16458126
references: Endocrine. 2005 Nov;28(2):157-63
references: 16388088
references: J Lipid Res. 1996 Oct;37(10):2065-73
references: 8906584
references: Lipids Health Dis. 2010 Sep 07;9:96
references: 20822508
references: Circulation. 2004 Jun 15;109(23 Suppl 1):III33-8
references: 15198964
references: Atherosclerosis. 2008 Feb;196(2):953-7
references: 17399717
references: Methods Enzymol. 1986;129:716-38
references: 3724551
references: Atheroscler Suppl. 2008 Sep;9(2):39-44
references: 18595782
references: J Lipid Res. 2004 Nov;45(11):1967-74
references: 15342674